Decay-accelerating factor 1 (Daf1) deficiency exacerbates xenobiotic-induced autoimmunity

Immunology

Volumn 131, Issue 1, 2010, Pages 99-106

  Toomey, Christopher B ^a   Cauvi, David M ^a,c   Song, Wen Chao ^b   Pollard, Kenneth M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

autoantibodies; CD97; cytokines; decay accelerating factor 1 (Daf1, CD55); mercuric chloride; T cell activation

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CD3 ANTIBODY; CD97 ANTIGEN; CHROMATIN ANTIBODY; CYTOKINE; DECAY ACCELERATING FACTOR; DECAY ACCELERATING FACTOR 1; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; MERCURIC CHLORIDE; MESSENGER RNA; MONOCLONAL ANTIBODY CD28; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD55; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CYTOKINES; LYMPHOCYTE ACTIVATION; MERCURIC CHLORIDE; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES;

EID: 77955148831     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2010.03279.x     Document Type: Article

References (35)

1. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol, 1989 7 : 35 58.
2. Ruiz-Arguelles A, Llorente L. The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmun Rev, 2007 6 : 155 161.
3. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD, Song WC. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med, 2005 201 : 567 577.
4. Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol, 2007 179 : 5793 5802.
5. Sogabe H, Nangaku M, Ishibashi Y et al. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol, 2001 167 : 2791 2797.
6. Miwa T, Maldonado MA, Zhou L et al. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol, 2002 161 : 1077 1086.
7. Yanagawa B, Spiller OB, Choy J et al. Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab Invest, 2003 83 : 75 85.
8. Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, Xu Y, Medof ME. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med, 2005 201 : 1523 1530.
9. Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J, Spendlove I. Costimulation via CD55 on Human CD4+ T Cells Mediated by CD97. J Immunol, 2006 177 : 1070 1077.
10. Abbott RJ, Spendlove I, Roversi P et al. Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55. J Biol Chem, 2007 282 : 22023 22032.
11. Lea S. Interactions of CD55 with non-complement ligands. Biochem Soc Trans, 2002 30 : 1014 1019.
12. Qian YM, Haino M, Kelly K, Song WC. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology, 1999 98 : 303 311.
13. Veninga H, Becker S, Hoek RM et al. Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. J Immunol, 2008 181 : 6574 6583.
14. Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, Kelly K. CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood, 2005 105 : 2836 2844.
15. Cauvi DM, Cauvi G, Pollard KM. Reduced expression of decay-accelerating factor 1 on CD4+ T cells in murine systemic autoimmune disease. Arthritis Rheum, 2007 56 : 1934 1944.
16. Pollard KM, Hultman P, Kono DH. Using Single-Gene Deletions to Identify Checkpoints in the Progression of Systemic Autoimmunity. Ann N Y Acad Sci, 2003 987 : 236 239.
17. Kono DH, Balomenos D, Pearson DL, Park MS, Hildebrandt B, Hultman P, Pollard KM. The prototypic Th2 autoimmunity induced by mercury is dependent on IFN- gamma and not Th1/Th2 imbalance. J Immunol, 1998 161 : 234 240.
18. Ochel M, Vohr HW, Pfeiffer C, Gleichmann E. IL-4 is required for the IgE and IgG1 increase and IgG1 autoantibody formation in mice treated with mercuric chloride. J Immunol, 1991 146 : 3006 3011.
19. Pietsch P, Vohr HW, Degitz K, Gleichmann E. Immunological alterations inducible by mercury compounds. II. HgCl2 and gold sodium thiomalate enhance serum IgE and IgG concentrations in susceptible mouse strains. Int Arch Allergy Appl Immunol, 1989 90 : 47 53.
20. Hu H, Moller G, Abedi-Valugerdi M. Mechanism of mercury-induced autoimmunity: both T helper 1- and T helper 2-type responses are involved. Immunology, 1999 96 : 348 357.
21. Hamann J, Vogel B, van Schijndel GM, van Lier RA. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med, 1996 184 : 1185 1189.
22. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci U S A, 1999 96 : 628 633.
23. Pollard KM, Arnush M, Hultman P, Kono DH. Costimulation requirements of induced murine systemic autoimmune disease. J Immunol, 2004 173 : 5880 5887.
24. An F, Li Q, Tu Z, Bu H, Chan CC, Caspi RR, Lin F. Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis. Invest Ophthalmol Vis Sci, 2009 50 : 3778 3782.
25. Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest, 2002 110 : 1269 1274.
26. Miwa T, Maldonado MA, Zhou L, Yamada K, Gilkeson GS, Eisenberg RA, Song WC. Decay-Accelerating Factor Ameliorates Systemic Autoimmune Disease in MRL/lpr Mice via Both Complement-Dependent and -Independent Mechanisms. Am J Pathol, 2007 170 : 1258 1266.
27. Liu J, Lin F, Strainic MG et al. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J Immunol, 2008 180 : 5882 5889.
28. Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev, 2008 226 : 87 80.
29. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol, 2009 27 : 485 517.
30. Tigno-Aranjuez JT, Jaini R, Tuohy VK, Lehmann PV, Tary-Lehmann M. Encephalitogenicity of complete freund's adjuvant relative to CpG is linked to induction of Th17 cells. J Immunol, 2009 183 : 5654 5661.
31. Haggqvist B, Hultman P. Interleukin-10 in murine metal-induced systemic autoimmunity. Clin Exp Immunol, 2005 141 : 422 431.
32. Pollard KM, Pearson DL, Hultman P, Deane TN, Lindh U, Kono DH. Xenobiotic acceleration of idiopathic systemic autoimmunity in lupus- prone bxsb mice. Environ Health Perspect, 2001 109 : 27 33.
33. Haggqvist B, Hultman P. Murine metal-induced systemic autoimmunity: baseline and stimulated cytokine mRNA expression in genetically susceptible and resistant strains. Clin Exp Immunol, 2001 126 : 157 164.
34. Abbott RJM, Spendlove I, Roversi P et al. Structural and functional characterisation of a novel TCR co-regulatory protein complex: CD97-CD55. J Biol Chem, 2007 282 : 22023 22032.
35. Lawson BR, Prud'homme GJ, Chang Y, Gardner HA, Kuan J, Kono DH, Theofilopoulos AN. Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J Clin Invest, 2000 106 : 207 215.